KROS Sep 2024 75.000 call
| Previous close | 4.3900 |
| Open | 4.3900 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 75.00 |
| Expiry date | 2024-09-20 |
| Day's range | 4.3900 - 4.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireKeros Therapeutics Announces Leadership Updates
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced changes to its Board of Directors (“Board”) and Executive Committee, effective July 1, 2024. Keros’ Boa
- GlobeNewswire
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by obse
- GlobeNewswire
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that the Company will host a corporate update conference call and webcast on Monday, June 17, 2024 at 8
